BPC-157
Also known as: Body Protection Compound-157, Pentadecapeptide BPC 157
Key Facts: BPC-157
- Category
- Healing
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical - FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026; formal FDA publication pending)
- Administration
- Subcutaneous injection near injury site, or systemic
- Typical Dose
- 250-500 mcg twice daily
- Frequency
- 1-2x daily
- Duration
- 4-12 weeks in most research protocols
Mechanism of Action
BPC-157 modulates the nitric oxide system, promotes angiogenesis (new blood vessel formation), and upregulates growth hormone receptors. It also interacts with the dopaminergic system and has been shown to accelerate tendon-to-bone healing by promoting collagen synthesis.
Research Summary
Extensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract. 2025 AJSM systematic review: Of 544 articles screened, only 1 clinical study met inclusion criteria (rest were animal studies). Only 3 small human pilot studies exist (fewer than 30 total subjects). No pharmaceutical company has initiated FDA trials due to lack of patentability. FDA placed BPC-157 in Category 2 in September 2023.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
250-500 mcg twice daily
200-1,000 mcg per day total
1-2x daily
Often injected subcutaneously near injury site for localized healing. Systemic administration also common. Many users split into morning and evening doses.
Research Dosingⓘ
Scientific studies
Doses observed in research studies
Doses from Studies
250-500 mcg twice daily
200-300 mcg/kg in animal studies
Duration
4-12 weeks in most research protocols
Administration
Subcutaneous injection near injury site, or systemic
Timing & Administration
Best Time to Take
Morning and evening (or near injury site timing)
1-2 times daily, consistent timing
Food Recommendation
With or without food
Why This Timing?
BPC-157 has systemic healing effects. Split dosing maintains stable levels. Can be timed around activity for injury healing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated in preclinical studies
- ●Nausea
- ●Dizziness
- ●Injection site reactions
- ●Fatigue
- ●Headache
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●Potential concern for tumor promotion (angiogenesis)
- ●Limited long-term human safety data
References
- https://pubmed.ncbi.nlm.nih.gov/21030672/
- https://pubmed.ncbi.nlm.nih.gov/30915550/
- https://pubmed.ncbi.nlm.nih.gov/14554208/
Research This Peptide Further
Frequently Asked Questions
What does BPC-157 do?
A synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.
How does BPC-157 work?
BPC-157 modulates the nitric oxide system, promotes angiogenesis (new blood vessel formation), and upregulates growth hormone receptors. It also interacts with the dopaminergic system and has been shown to accelerate tendon-to-bone healing by promoting collagen synthesis.
Is BPC-157 FDA approved?
No, BPC-157 is not currently FDA approved. Current status: Preclinical - FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026; formal FDA publication pending)
What are the side effects of BPC-157?
Reported side effects include: Generally well-tolerated in preclinical studies, Nausea, Dizziness, Injection site reactions, Fatigue. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of BPC-157?
Community-reported common dose: 250-500 mcg twice daily (1-2x daily). Range: 200-1,000 mcg per day total. Administration: Subcutaneous injection near injury site, or systemic. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with BPC-157 or used in similar applications.
TB-500
PreclinicalA synthetic 17-amino acid fragment of Thymosin Beta-4 (TB-4). Unlike TB-4, TB-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. Note: Many vendors mislabel TB-4 as 'TB-500' in premixed products.
HealingGHK-Cu
Clinical TrialsA naturally occurring copper-binding peptide found in human plasma, saliva, and urine. Widely used in skincare for its wound healing and anti-aging properties.
Skin & HairPentadecapeptide
PreclinicalThe full 15-amino acid sequence that includes BPC-157. While BPC-157 is more commonly discussed, the full pentadecapeptide has similar healing properties derived from gastric juice.
HealingThymosin Beta-4
Clinical TrialsThe full 43-amino acid protein that TB-500 is derived from. Naturally occurring in most human tissues, TB-4 has a shorter half-life (~2 hours) compared to its synthetic fragment TB-500 (~2-4 days). Often mislabeled as 'TB-500' by vendors in premixed products.
HealingZiconotide
FDAA synthetic cone snail venom peptide for severe chronic pain. The first intrathecal non-opioid analgesic FDA approved.
HealingWolverine Stack
PreclinicalThe most popular healing peptide combination, combining BPC-157 (10mg) and TB-500 (10mg). Named after the Marvel character's regenerative abilities. Used for accelerated injury recovery, joint support, and tissue repair.
Peptide BlendWant updates on BPC-157 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.